养血清脑颗粒联合盐酸氟桂利嗪胶囊治疗急性脑梗死伴头痛患者的疗效

目的 探讨养血清脑颗粒联合盐酸氟桂利嗪胶囊治疗急性脑梗死伴头痛患者的疗效。方法 110例急性脑梗死伴头痛患者入院后随机分为两组，对照组（55例）给予盐酸氟桂利嗪胶囊治疗，5 mg/次，晚间服用；观察组（55例）给予养血清脑颗粒联合盐酸氟桂利嗪胶囊治疗，养血清脑颗粒4 g/次，3 次/d；盐酸氟桂利嗪胶囊5 mg/次，晚间服用。疗程均为4周。依据两组疗效，治疗前和治疗后2、4周的头痛积分、日常生活能力（ADL）评分及治疗期间不良反应情况，评价养血清脑颗粒联合盐酸氟桂利嗪胶囊治疗急性脑梗死伴头痛患者的疗效。结果 观察组治愈25例，显效19例，有效6例，有效率90.9%，对照组患者治愈18例，显效12例，有效13例，有效率78.2%，两者相比，差异有统计学意义（P<0.05）。治疗前，两组头痛程度积分和发作频率积分相比，无统计学差异；治疗后2、4周，两组患者头痛程度积分和发作频率积分均明显降低，同组治疗前后比较差异有统计学意义（P<0.05）；且观察组头痛程度积分和发作频率均低于对照组，差异有统计学意义（P<0.05）。治疗前，两组ADL评分相比，无统计学差异；治疗后2、4周，两组ADL评分均明显提高，同组治疗前后比较差异有统计学意义（P<0.05）；且观察组ADL评分高于对照组，差异有统计学意义（P<0.05）。治疗期间，两组不良反应发生率无统计学差异。结论 养血清脑颗粒联合盐酸氟桂利嗪胶囊对急性脑梗死伴头痛患者具有较好的治疗效果，能明显减轻患者头痛，减少头痛发作频率，提高患者日常生活能力，用药具有安全性。

Efficacy of Yangxueqingnao Granule combined with Flunarizine Hydrochloride Capsules in treatment of acute cerebral infarction with headache

Objective Discuss the efficacy of Yangxueqingnao granule combined with Flunarizine Hydrochloride capsules in treatment of acute cerebral infarction with headache. Methods 110 patients with acute cerebral infarction with headache were selected, they were divided into two groups randomly. The control group (55 cases) was given Flunarizine Hydrochloride Capsules. The observation group (55 cases) was given Yangxueqingnao granule combined with Flunarizine Hydrochloride capsules. The efficacy of Yangxueqingnao granule combined with Flunarizine Hydrochloride capsules in treatment of acute cerebral infarction with headache was evaluated by the efficacy, headache symptom score, ADL scores and adverse reactions during treatment. Results 25 cases were cured in the observation group, markedly effective in 19 cases, effective in 6 cases, the effective rate was 90.9%; 18 cases were cured in the control group, markedly effective in 12 cases, effective in 13 cases, the effective rate was 78.2%. The effective rate was higher in the observation group (P<0.05). Before treatment, there were no statistical significance on headache scores in two groups. 2 and 4 weeks after treatment, the headache scores were decreased and the scores were lower in the observation group (P<0.05). Before treatment, there were no statistical significance on ADL scores between two groups. 2 and 4 weeks after treatment, the ADL scores were increased and the scores were higher in the observation group (P<0.05). During treatment, there were no statistical significance on adverse reaction between two groups. Conclusion Yangxueqingnao granule combined with Flunarizine Hydrochloride capsules have a good therapeutic effect on acute cerebral infarction with headache symptoms. The patients can significantly reduce headache and headache attack frequency. The therapy can improve the ability of daily life of patients with good safety.